Jun

Making Sense of the Current SPAC Market: Are SPACs still a viable pathway to going public?

Name: Making Sense of the Current SPAC Market: Are SPACs still a viable pathway to going public?
Start: 2021-06-09T09:00:00-06:00
End: 2021-06-09T10:00:00-06:00

Wednesday, Jun 9, 2021
9:00—10:00am

Within the past year the role in biotech of special purpose acquisition companies (SPAC) has moved from a rarefied interest to a core option for reaching public markets, now attracting high levels of investor and regulator attention. Learn through live Q&A with a panel of SPAC deal experts how this popular, volatile tool for raising capital works in
practice and will evolve next.

Find out more and register.

Moderated by:
Barbara Ryan, Founder, Barbara Ryan Advisors; Editorial Advisory Board, Pharmaceutical Executive; Senior Advisor, EY

Panelists:
Jonas Grossman, President and Managing Partner, Chardan
Rakhi Kumar, Chief Accounting Officer, Roivant Sciences
Ryan Maierson, Partner, Latham & Watkins LLP
Carlo Passeri, Director, Biotechnology Capital Markets, Biotechnology Innovation Organization (BIO)

Networking + Events

Making Sense of the Current SPAC Market: Are SPACs still a viable pathway to going public?